An experimental test based on the detection of a panel of autoantibodies could predict the occurrence of severe side effects or the recurrence of cancer in melanoma patients who have received immune checkpoint blockade immunotherapies, scientists at the Perlmutter Cancer Center in the NYU Grossman School of Medicine claim. The study included 950 patients with advanced melanoma who received adjuvant checkpoint inhibitor immunotherapy as part of two Phase III randomized controlled trials.
A candidate drug triggers Z-DNA conformations in cells that in turn activates a highly immunogenic programmed pathway of inflammatory cell death in cancer-associated fibroblasts. In mouse studies, researchers showed that the compound (CBL0137), a member of the curaxin family, rekindles immune responses against melanoma resistant to immune checkpoint blockade immunotherapy by mimicking influenza infections. Combining a "virus mimetic" immune adjuvant with immunotherapy may rekindle an immune response in otherwise unresponsive patients.
Scientists identify gut microbes associated with toxicity to combined checkpoint inhibitors in melanoma patients providing potential biomarkers for toxicity and treatment response. They also identify genomic and immune markers associated with combined immune therapy induced intestinal inflammation. The study investigates a potential new strategy to treat toxicity while maintaining response to combined immune checkpoint blockade through either IL-1R inhibition or manipulation of gut microbiota.
Scientists at the Moffitt Cancer Center & Research Institute compare the immune landscapes of leptomeningeal melanoma metastases (LMM) and melanoma brain metastases (MBM) using single-cell RNA-seq, identifying key differences in the tumor microenvironment that may result in the development of improved therapeutics.